Electronic Supplementary Material (ESI) for RSC Advances. This journal is © The Royal Society of Chemistry 2019

#### **Supplementary Information for**

# Iron Oxide Encapsulated by Copper-apatite: An efficient Magnetic Nanocatalyst for *N*-arylation of Imidazole with Boronic acid

### Othmane Amadine,<sup>a\*</sup> Younes Essamlali,<sup>a</sup> Abdallah Amedlous,<sup>a,b</sup> Mohamed

#### Zahouily a,b\*\*

a VARENA Center, MAScIR Foundation, Rabat Design, Rue Mohamed El Jazouli, Madinat El Irfane, 10100-Rabat, Morocco. E-mail: m.zahouily@mascir.com b Laboratoire de Matériaux, Catalyse et Valorisation des Ressources Naturelles, URAC 24, FST, Université Hassan II-Casablanca, Morocco

## **Table of Contents**

<ol> <li>General Procedure for the Coupling of boronic acid with Imidazole</li> <li>General Procedure for the Coupling of boronic acid with Indole</li> <li><sup>1</sup>H NMR Spectra of N-arylImidazole</li> </ol>	S2 S2 S3		
		4. <sup>1</sup> H NMR Spectra of N-arylIndole	<b>S</b> 9

- General Procedure for the *N*-arylation of imidazole : In a 50 mL round-bottomed flask, imidazole (1 mmol), phenylboronic acid (1.2 mmol), K<sub>2</sub>CO<sub>3</sub> (1.5 mmol) and Fe<sub>3</sub>O<sub>4</sub>@Cuapatite (15 mol%) were added and stirred in MeOH under air at 60°C for the required time, monitoring by TLC. After completion, the mixture was diluted with H<sub>2</sub>O and the product was extracted with EtOAc (3 times). The combined extracts were washed with brine (3 times) and dried over Na<sub>2</sub>SO<sub>4</sub>. The product was purified using column chromatography (60– 120 mesh silica gels, eluting with EtOAc– hexane).
- 2. General Procedure for the *N*-arylation of indole : In a 50 mL round-bottomed flask, indole (1 mmol), phenylboronic acid (1.2 mmol), K<sub>2</sub>CO<sub>3</sub> (1.5 mmol) and Fe<sub>3</sub>O<sub>4</sub>@Cu-apatite (15 mol%) were added and stirred in MeOH under air at 60°C for the required time, monitoring by TLC. After completion, the mixture was diluted with H<sub>2</sub>O and the product was extracted with EtOAc (3 times). The combined extracts were washed with brine (3 times) and dried over Na<sub>2</sub>SO<sub>4</sub>. The product was purified using column chromatography (60–120 mesh silica gels, eluting with EtOAc– hexane).
- 3. The structures of the prepared products were confirmed by <sup>1</sup>H NMR and assigned on the basis of their spectral data in comparison with those reported in the literature.

*N*-Phenylimidazole (Table 4, entry 1) : <sup>1</sup>H NMR (DMSO-*d*6): δ 8.36 (s, 1H), 7.88 (t, 1H), 7.46 (q, *J*= 5.8 Hz, 2H), 7.38 (t, 2H), 7.33 (t, 1H), 7.29 (s, 1H).



Fig. S1: <sup>1</sup>H NMR spectrum of the *N*-Phenylimidazole

**1-***p***-Tolyl-1***H***-imidazole (Table 4, entry 2) : <sup>1</sup>H NMR (CDCl3): δ8.36 (s, 1H), 7.31 (s, 1H), 7.25 (d,** *J***= 6.8 Hz, 2H), 7.17 (d,** *J***= 7.2Hz, 2H), 7.15 (s, 1H), 2.36 (s, 3H). M/Z= 158.** 



**Fig. S2:** <sup>1</sup>H NMR spectrum of the 1-*p*-Tolyl-1*H*-imidazole

**1-***m***-Tolyl-1***H***-imidazole (Table 4, entry 3) : <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 8.36 (s, 1H), 7.89 (s, 1H), 7.30 (s, 1H), 7.25 (t, 2H), 7.20 (t,** *J***= 7.0 Hz, 1H), 7.04 (1H, s), 2.36 (3H, s).** 



Fig. S3: <sup>1</sup>H NMR spectrum of the 1-m-Tolyl-1H-imidazole

**1**-*ortho*-**Tolyl**-1*H*-**imidazole (Table 4, entry 4) :** <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.32 (bs, 1H), 7.33-7.30 (m, 3H), 7.29-7.20 (m, 2H), 7.15 (bs, 1H), 2.26 (s, 3H).



Fig. S4: <sup>1</sup>H NMR spectrum of the 1-ortho-Tolyl-1H-imidazole

**1-(4-Methoxy-phenyl)-1***H***-imidazole (Table 4, entry 5) :** <sup>1</sup>H NMR (DMSO-*d*6): δ8.36 (s, 1H), 7.89 (s, 1H), 7.29 (d, *J*= 8.8 Hz, 2H), 6.96 (d, *J*=8.8 Hz, 3H), 3.80 (s, 3H).



Fig. S5: <sup>1</sup>H NMR spectrum of the 1-(4-Methoxy-phenyl)-1H-imidazole

**1-(4-Nitrophenyl)-1***H***-imidazole (Table 4, entry 6) :** <sup>1</sup>H NMR (CDCl3-*d*6): δ8.36-8.26 (m, 2 H), 7.89 (s, 1 H), 7.58-7.55 (m, 2 H), 7.32 (s, 1 H), 7.31 (d, *J*= 8.8 Hz, 1 H).



**Fig. S6:** <sup>1</sup>H NMR spectrum of the 1-(4-Nitrophenyl)-1*H*-imidazole

**N-Phenylindole (Table 4, entry 7) :** yellow oil, <sup>1</sup>H NMR (CDCl<sub>3</sub>) : δ 6.70 (dd, 1H, J = 3.3 and 0.9 Hz), 7.18-7.30 (m, 2H), 7.35-7.42 (m, 2H), 7.53-7.56 (m, 4H), 7.59-7.63 (m, 1H), 7.71-7.76 (m, 1H).



Fig. S7: <sup>1</sup>H NMR spectrum of the *N*-Phenylindole

**N-(4-Methylphenyl)indole (Table 4, entry 8)** : <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.76 (d, J ) 7.8 Hz, 1H), 7.70 (d, J ) 8.2 Hz, 1H), 7.60 (d, J ) 7.8 Hz, 2H), 7.36-7.34 (m, 3H), 7.23 (t, J ) 7.8 Hz, 1H), 7.18 (t, J ) 7.8 Hz, 1H), 6.69 (d, J ) 2.4 Hz, 1H), 2.36 (s, 3H).



Fig. S8: <sup>1</sup>H NMR spectrum of the N-(4-Methylphenyl)indole

**1-(3-Methylphenyl)indole (Table 4, entry 9) :** <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ: 7.69 (d, J=7.5 Hz, 1H), 7.58 (d, J=8.1 Hz, 1H), 7.42—7.30 (m, 4H), 7.25—7.14 (m, 3H), 6.68 (d, J=3.3 Hz, 1H), 2.33 (s, 3H).



Fig. S9: <sup>1</sup>H NMR spectrum of the N-(3-Methylphenyl)indole

**1-(2-Methylphenyl)indole (Table 4, entry 10):** <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ: 7.76—7.62 (m, 1H), 7.31—7.20 (m, 4H), 7.18—7.15 (m, 3H), 7.14—7.12 (m, 1H), 6.67 (d, J = 3.3 Hz, 1H), 2.30 (s, 3H).



Fig. S10: <sup>1</sup>H NMR spectrum of the N-(2-Methylphenyl)indole

**N-(4-Methoxyphenyl)indole (Table 4, entry 11) :** white powder, <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.83 (s, 3H), 6.69 (dd, 1H, J = 3.3 and 0.9 Hz), 7.13-7.16 (m, 2H), 7.21-7.33 (m, 2H), 7.35 (d, 1H, J = 3.0 Hz), 7.34-7.35 (m, 2H), 7.59-7.61 (m, 1H), 7.69-7.73 (m, 1H).



Fig. S11: <sup>1</sup>H NMR spectrum of the N-(4-Methoxyphenyl)indole

**1-(4-Nitrophenyl)-1H-indole (Table 4, entry 12) :** Yellow solid, <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta = 6.71$  (1H, d, J = 3.2 Hz), 7.16 (2H, m), 7.23 (1H, d, J = 3.6 Hz), 7.64 (4H, m), 8.22 (2H, d, J = 8.8 Hz).



Fig. S12: <sup>1</sup>H NMR spectrum of the 1-(4-Nitrophenyl)-1H-indole